Irinotecán Hospira

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecán Hospira, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, particularly in advanced or metastatic disease, and is administered under the supervision of an oncologist.

GNH USA supplies Irinotecán Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company ensures quality compliance with EU standards and provides reliable global distribution.

Irinotecan is indicated for colorectal cancer and related disease states where tumor growth must be controlled.

- Metastatic colorectal cancer: used as part of combination chemotherapy to reduce tumor burden. - Advanced colorectal cancer: administered to improve progression‑free survival. - Refractory colorectal cancer: employed when disease progresses after prior therapies.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: often severe and may require medical management. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: general tiredness experienced during treatment. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair.

Serious or Rare Side Effects: - Severe intestinal toxicity (colitis): can lead to perforation. - Febrile neutropenia: fever with low neutrophil count. - Hepatotoxicity: liver enzyme elevations or injury. - Hypersensitivity reactions: including rash, bronchospasm, or anaphylaxis.

When using Irinotecán Hospira, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check enzymes before and during therapy. - Manage diarrhea promptly: initiate antidiarrheal agents at first sign. - Avoid in patients with known hypersensitivity to irinotecan or its excipients. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with other medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia. - Concurrent use with other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Antiemetics (e.g., aprepitant): may alter irinotecan metabolism. - Diuretics: watch for electrolyte disturbances during diarrhea.